Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Monday. The firm set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

ONCT stock opened at $0.53 on Monday. Oncternal Therapeutics has a 1 year low of $0.53 and a 1 year high of $9.88. The stock’s fifty day moving average price is $0.53 and its 200-day moving average price is $0.71. The company has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.